Literature DB >> 1056158

Complications of BCG vaccination in neoplastic disease.

C W Aungst, J E Sokal, B V Jager.   

Abstract

More than 300 patients with neoplastic disease (most with lymphoma or leukemia) were given one or more BCG vaccinations. In the great majority of cases, these were well tolerated. The complications we observed were of three types: (A) persistent BCG infection that could disseminate widely, (B) activation of old, dormant acid-fast infection, and (C) hypersensitivity reactions. The latter were related to the frequency of administration and dose of organisms. It is important to recognize that BCG organisms may not be completely destroyed by patients with impaired immunologic defenses, and that their inoculation may create a source of disseminated acid-fast infection at a later time. In our limited experience, treatment with isoniazid for 2 to 3 months has resulted in cure of BCG infection. Hypersensitivity reactions may constitute a more serious problem than such infections.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1056158     DOI: 10.7326/0003-4819-82-5-666

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Synergistic anti-suppressor effect of mini cells prepared from Salmonella typhimurium and mitomycin C in EL 4-bearing mice.

Authors:  S Kurashige; Y Akuzawa; S Mitsuhashi
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

2.  Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial).

Authors:  H M Jansen; T H The; G C de Gast; M T Esselink; A M van der Wal; N G Orie
Journal:  Thorax       Date:  1978-08       Impact factor: 9.139

3.  Pulmonary tuberculosis due to bacille Calmette-Guérin.

Authors:  D Kirsten; U Rieger; K H Schröder; A Böhle; H Magnussen
Journal:  Clin Investig       Date:  1993-10

4.  Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes.

Authors:  J M Douglas; L A Vontver; W E Stamm; W C Reeves; C Critchlow; M L Remington; K K Holmes; L Corey
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

5.  Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial.

Authors:  T Ochiai; H Sato; R Hayashi; T Asano; H Sato; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Pityriasis rosea-like rash secondary to intravesical bacillus calmette-guerin immunotherapy.

Authors:  Chee Won Oh; Jimi Yoon; Chi Yeon Kim
Journal:  Ann Dermatol       Date:  2012-07-25       Impact factor: 1.444

Review 7.  Translation of peptidoglycan metabolites into immunotherapeutics.

Authors:  Matthew E Griffin; Charles W Hespen; Yen-Chih Wang; Howard C Hang
Journal:  Clin Transl Immunology       Date:  2019-11-29

8.  Pulmonary granulomas in a patient on MER therapy.

Authors:  J Lundy; I Damjanov; M Ballow; M Henken; M S Mitchell
Journal:  Yale J Biol Med       Date:  1977 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.